Part 4/8:
One of the primary obstacles highlighted by Romer is the current regulatory environment. He criticizes the Food and Drug Administration (FDA) for restricting the production and deployment of new testing methods unless explicitly authorized. The rigidity has hindered rapid innovation, even as university labs and independent researchers have developed alternative approaches to testing, such as using different reagents or sample collection techniques.